Atherogenic lipoproteins

Biomarker1 paper1 finding

Interventions

Sirna therapeutics

downin reviews1

1 study

Sirna therapeutics decrease atherogenic lipoproteins.
Reviewhepatocyte-directed
Small Interfering RNA in Cardiovascular Disease: A New Frontier in Precision Medicine · Annual review of pharmacology and toxicology · 7 Oct 2026

Sirna therapeutics →

Latest

Annual Review of Pharmacology and ToxicologyReviewYesterday

Small Interfering RNA in Cardiovascular Disease: A New Frontier in Precision Medicine

Cardiovascular disease

Current Atherosclerosis ReportsReview1 Oct

Non-HDL Cholesterol as a Predictor of Coronary Atherosclerosis in South Asians: A Narrative Review

Non-HDL cholesterol

Journal of Diabetes and Metabolic DisordersHumans28 Sep

Discordantly high apolipoprotein B despite normal LDL cholesterol across AHA PREVENT cardiometabolic risk strata among U.S. adults

Apolipoprotein B

Journal of Diabetes and Metabolic DisordersHumans28 Sep

Cumulative non-HDL cholesterol is linked to CVD risk

Each 100-unit increase in cumulative exposure was associated with an adjusted hazard ratio of 1.07 for cardiovascular disease over nine years, driven…Each 100-unit increase in cumulative exposure was associated with an adjusted hazard ratio of 1.07 for cardiovascular disease over nine years, driven by earlier stages.

Cardiovascular disease

BiomedicinesHumans26 Sep